Loading organizations...
Lightswitch Capital operates as a private equity firm, primarily investing in and partnering with private companies across healthcare and biotechnology. The firm provides strategic capital and operational support, focusing on enterprises that develop innovative solutions. Its investment approach aims to accelerate growth and enhance market presence for portfolio companies within the health ecosystem.
Christopher Nixon Cox, Chief Executive Officer, founded Lightswitch Capital. Cox established the firm driven by an insight into significant opportunities within the healthcare and biotech innovation landscape. His leadership and professional background inform the firm's investment philosophy, guiding its strategic engagement with promising portfolio companies.
Lightswitch Capital's partners are private healthcare and biotech ventures requiring capital and strategic expertise. The firm's vision is to contribute to the healthcare industry's evolution by empowering enterprises poised for substantial impact. It actively seeks opportunities aligning with its commitment to advancing medical and biotechnological solutions.
Lightswitch Capital has 2 tracked investments across 2 companies. The latest tracked deal is $45.0M Series C in Alto Neuroscience in November 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 1, 2023 | Alto Neuroscience | $45.0M Series C | Michael Liang | 7BC Venture Capital, Baird Capital, Champion Hill Labs, Crosscut Ventures, Endeavor Venture Funds, Scott Hartley, LombardStreet Ventures, Presight Capital, What IF Ventures, TIM Kendall, Alexandria Venture Investments, Alpha Wave Ventures, ELI Lilly And Company, Franklin Templeton, Point72, Windham Venture Partners |
| May 16, 2022 | Kriya Therapeutics | $270.0M Series C | JIM Momtazee | Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Narya Capital, QVT, Transhuman Capital |
